Adeno-associated virus (AAV) vectors have become pivotal in the clinical development of gene therapies. Christopher Reardon, Dyno Therapeutics, Cambridge, MA, describes challenges associated with using AAV vectors, including regulatory barriers. Despite a small number of gene therapies successfully being approved, the pathway for regulating this novel technology requires consolidation and optimization. This interview took place at Advanced Therapies Week 2022.
Christopher Reardon is an employee of Dyno Therapeutics.